Baker Hughes Company (BKR) Balance Sheet

The trajectory over the ten-quarter window is bifurcated: a stable, slowly compounding industrial balance sheet through 2025Q4, followed by an abrupt re-basing across 2026Q1 through 2026Q3. Roughly two-thirds of the $18.2B asset expansion since 2025Q4 sits in goodwill and intangibles rather than in PPE, which grew a more modest $0.9B over the same span, suggesting balance sheet growth is being purchased rather than built. Investors should treat the pre- and post-2026 periods as structurally different entities when benchmarking asset turns or capital intensity.

The leverage shift appears strategically motivated rather than distress-driven, since the $11.2B debt build coincides with the disclosed $14.2B acquisition outflow rather than with operating shortfalls. However, net debt swung from approximately $0.6B in 2026Q2 to roughly $14.2B in 2026Q3, which suggests the company has moved from a net-cash posture to a meaningfully net-levered one in a single quarter. Refinancing risk therefore looks less about maturities than about whether operating cash flow, which prior analysis shows to be volatile quarter to quarter, can service this new base.

Goodwill now equals approximately 58% of shareholders' equity, meaning more than half of the book capital supporting the balance sheet rests on the assumed durability of acquired cash flows rather than on separable, realizable assets. This appears consistent with the company's stated industrial-technology positioning, where acquired engineering and digital capability is the asset being purchased, but it also concentrates impairment risk in a single line item during an energy capital-spending downturn. Net PPE growth of 36% over the window to $6.8B does suggest the manufacturing footprint was not neglected, though the PPE-to-assets ratio has nonetheless fallen.

The 2026Q2 cash balance of $15.7B now looks like temporary deal-funding escrow rather than a durable operating buffer, and the return to a 1.24 current ratio suggests the company is operating with less shock absorption than the prior two quarters implied. That said, a 1.24 ratio is in line with where the balance sheet sat through 2024, so this is arguably normalization rather than deterioration. Combined with the deferred revenue build, the working capital structure may remain self-funding even at a thinner cash line, but investors should monitor whether the current ratio drifts below its historical 1.27-1.41 band.

The acceleration from $6.0B in 2026Q1 to $8.0B in 2026Q3 outpaces the organic revenue growth profile, which suggests either larger customer milestone payments or a shift in contract terms toward more favorable billing. For a business utilizing percentage-of-completion accounting, a rising deferred balance is a constructive leading indicator because it represents cash already collected against revenue not yet recognized, effectively a free source of operating funding. Investors should monitor whether this line converts into margin at the disclosed 24% gross margin, since a build driven by lower-margin equipment prepayments would dilute rather than enhance earnings quality.